Material Insights · Understanding the Material World

Stent: Supply chain

Main companies

The largest makers and their shares

CompanyCountryMeasureYearSource
Abbott Vascular, Boston Scientific and Medtronic– Named as the foreign stent companies in India [10]; multinationals together held around 60% of India's market in 2016 [9]. No world shares found2016[10][9]
Meril Life SciencesIndiaProduces more than 60,000 stents every year (MD+DI, 2013). No market share found2013[15]
Johnson & Johnson (Cordis)United States of AmericaLaunched the Palmaz-Schatz stent in the United States in 1994 [7]; its Cypher (with Cordis) was the first drug-eluting stent approved by the FDA, in 2003 [8]. No share found2003[7][8]
Cook MedicalUnited States of AmericaMaker of the Gianturco-Roubin Flex-Stent, approved by the FDA in 1993 and already marketed in Australia, Korea and Singapore. No share found1993[6][22]
Medtronic– Company segment, not stent output: Coronary & Peripheral Vascular had revenue of USD 2,535 million in fiscal 2025 (table value); the segment also sells guide catheters and balloons2025[21]

as of 2026-11-13

Supply chains of the main makers

For the top three to five producing countries and India: share, where inputs and components come from, main makers and how variants differ

CountryInputs fromMakersHow variants differYearSource
IndiaNo source opened says where India's stent materials come fromIndian makers such as Meril Life Sciences [15]; multinationals Abbott Vascular, Boston Scientific and Medtronic [10]Indigenous stents held under 40% of the market and multinationals around 60% in 2016; over 60% of drug-eluting stents were made by multinationals [9]2016[9][10][15]

as of 2026-11-13

Industries that make it

The industries and kinds of firm that make it

Made by
  • Medical-device companies (OEMs) World Device firms such as Abbott Vascular, Boston Scientific, Medtronic and Johnson & Johnson (Cordis) make stents [10][7].

as of 2026-11-13

Rules and standards

Labels, efficiency and emission standards, producer responsibility, bans and tariffs

RulePlaceYearWhat it doesSource
NPPA notification S.O. 412(E): ceiling prices of coronary stentsIndia2017Capped bare metal stents at INR 7,260 and drug-eluting stents at INR 29,600; the drug-eluting cap covers bioresorbable scaffolds too[11][9][23][13]
NPPA notification S.O. 639(E): revised ceiling pricesIndia2018Revised the caps to INR 27,890 for drug-eluting and INR 7,660 for bare metal stents, from INR 30,180 and INR 7,400 [11]; hospitals that bill patients directly must keep to the ceiling and list the stent's cost, type, brand and maker on the bill [25][11][25]
Coronary stents added to the National List of Essential Medicines, 2015 and to Schedule I of the Drugs (Prices Control) Order, 2013India2016Added to the list on 19 July 2016 and to Schedule I on 21 December 2016, which brings stents under NPPA ceiling prices[23][25]
CDSCO classification of devices under the Medical Devices Rules, 2017 (notice of 1 November 2017)India2017Lists the coronary stent, the bioresorbable vascular scaffold system and the drug-eluting stent in risk class D[14]
Premarket approval of drug-eluting stents, for example PMA P070015 for the XIENCE VUnited States of America2008The FDA publishes a summary of safety and effectiveness for each approved drug-eluting stent[3]
Regulation (EU) 2017/745, Annex VIII, Rule 8European Union2017Implants in direct contact with the heart or central circulatory system, which the Annex defines to include the coronary arteries, are class III[19]

as of 2026-11-13

India

India's output, trade, makers and rules in a short paragraph

One estimate puts stents used in India at 594,000 in 2016, with multinationals holding around 60% of the market [9]. NPPA fixed ceiling prices on 13 February 2017 and revised them on 12 February 2018 [11]; in February 2026 the ceilings were INR 10,692.69 for bare metal and INR 38,933.14 for drug-eluting stents [25]. Trade margins before the cap were up to 654% [12]. CDSCO lists coronary stents in risk class D [14]. No source opened gives output or imports.

as of 2026-11-13

Trade

World exports, the top exporters and importers and India, from UN Comtrade by HS code (worked out by the site)

FlowValueUnitVolumeUnitYearSource
World exports18.4USD billion30.2thousand tonnes2024UN Comtrade, HS 9021.90
Average export value (calculated)609.28USD per kg– – 2024UN Comtrade, HS 9021.90
Exporter: United States (15.5% of world exports)2.85USD billion2.6thousand tonnes2024UN Comtrade, HS 9021.90
Exporter: Netherlands (15.2% of world exports)2.79USD billion– – 2024UN Comtrade, HS 9021.90
Exporter: Ireland (13.2% of world exports)2.43USD billion0.7thousand tonnes2024UN Comtrade, HS 9021.90
Exporter: Germany (11.0% of world exports)2.02USD billion1.7thousand tonnes2024UN Comtrade, HS 9021.90
Exporter: Malaysia (5.7% of world exports)1.04USD billion– – 2024UN Comtrade, HS 9021.90
India exports (rank 24, 0.3% of world)0.06USD billion0.3thousand tonnes2024UN Comtrade, HS 9021.90
India imports (rank 17, 1.6% of world)0.27USD billion0.5thousand tonnes2024UN Comtrade, HS 9021.90
Importer: United States (11.7% of world imports)1.97USD billion1.9thousand tonnes2024UN Comtrade, HS 9021.90
Importer: Netherlands (11.3% of world imports)1.91USD billion3.5thousand tonnes2024UN Comtrade, HS 9021.90
Importer: Germany (9.8% of world imports)1.66USD billion3.3thousand tonnes2024UN Comtrade, HS 9021.90

Worked out from data

Sources

  1. Summary of Safety and Effectiveness Data, XIENCE V Everolimus Eluting Coronary Stent System (PMA P070015) US Food and Drug Administration (applicant Abbott Vascular, Cardiac Therapies), 2008, FDA notice of approval 2 July 2008; device description
  2. Inception of the coronary stent: a story of successful collaboration between innovative scientists and the biotechnology industry REC: Interventional Cardiology 6(4):321-331 (Macaya-Ten, Gonzalo, Escaned, Macaya), 2024
  3. The Surprising History Behind an Extremely Common Cardiovascular Medical Device MD+DI, no byline or date shown on the page
  4. Stents at 25 years: A revolution in revascularization Healio (Cardiology Today, Brian Ellis), 2011, dated April 01, 2011
  5. The new pricing policy for coronary stents in India: a boon or a bane? EuroIntervention (Upendra Kaul), 2017, EuroIntervention 2017;13(3), published 20 June 2017, DOI 10.4244/EIJV13I3A40
  6. Price-cap is after all just a new price: The case of cardiac stents in India Observer Research Foundation (Ramesh Bhat and Denny John), 2017, Issue Brief, published 27 April 2017; Table 1, estimates compiled by the authors from National Intervention Council presentations and reports
  7. Lok Sabha Unstarred Question No. 2781, Guidelines by NPPA, answered 13 March 2018 Lok Sabha, Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals), 2018
  8. Lok Sabha Unstarred Question No. 681, Trade Margins on Medical Devices, answered 19 December 2017 Lok Sabha, Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals), 2017
  9. NPPA puts price cap on cardiac stents; says hospitals overcharge Down To Earth (Kundan Pandey), 2017, published 14 February 2017
  10. Classification of medical devices and in vitro diagnostic medical devices under the provisions of the Medical Devices Rules, 2017 - Reg. Central Drugs Standard Control Organisation (Drugs Controller General of India), 2017, File No. 29/Misc.13/2017-DC(292), dated 1 November 2017; list entries 9, 10 and 205
  11. Indian Stent Makers Give Boston Sci, Medtronic, and Abbott a Run for Their Money MD+DI, 2013, dated 14 January 2013; no author named
  12. Regulation (EU) 2017/745 of the European Parliament and of the Council, Annex VIII (classification rules, original version) legislation.gov.uk (retained EU text), 2017
  13. Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase Medtronic, 2025, dated 21 May 2025; Worldwide Revenue table, (in millions)
  14. Cook's Gianturco-Roubin Flex-Stent is first coronary stent approved by FDA (title from the page address; the page text shows no headline) The Gray Sheet, on Medtech Insight (Informa), no date shown; the text gives the FDA panel of May 1992 and approval on 'May 28', which REC (2024) places in 1993
  15. Mission to provide Affordable, Quality Healthcare for All: Coronary Stent Prices capped, to bring down cost by about 380% Press Information Bureau, Government of India (Ministry of Chemicals and Fertilizers), 2017, posted 14 February 2017
  16. Increase in the Price of Cardiac Stents Press Information Bureau, Government of India (Ministry of Chemicals and Fertilizers), 2026, dated 13 February 2026